GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (STU:2RZ) » Definitions » Debt-to-Revenue

Poseida Therapeutics (STU:2RZ) Debt-to-Revenue : 0.75 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Poseida Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €5.52 Mil. Poseida Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €72.28 Mil. Poseida Therapeutics's annualized Revenue for the quarter that ended in Mar. 2024 was €103.56 Mil. Poseida Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.75.


Poseida Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Poseida Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poseida Therapeutics Debt-to-Revenue Chart

Poseida Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A 1.96 0.68 1.32

Poseida Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 1.09 2.31 0.85 0.75

Competitive Comparison of Poseida Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Poseida Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poseida Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's Debt-to-Revenue falls into.



Poseida Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Poseida Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.457 + 72.876) / 59.333
=1.32

Poseida Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.515 + 72.281) / 103.564
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Poseida Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Poseida Therapeutics (STU:2RZ) Business Description

Traded in Other Exchanges
Address
9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Poseida Therapeutics (STU:2RZ) Headlines

No Headlines